PPW
TCRT icon

Pasadena Private Wealth’s Alaunos Therapeutics TCRT Stock Holding History

Pasadena Private Wealth’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-71
Closed -$6.67K – 126
2023
Q1 		$6.67K Hold
71
– – ﹤0.01% 106
2022
Q4 		$6.88K Hold
71
– – ﹤0.01% 103
2022
Q3 		$18K Hold
71
– – 0.01% 88
2022
Q2 		$13K Hold
71
– – ﹤0.01% 89
2022
Q1 		$7K Hold
71
– – ﹤0.01% 98
2021
Q4 		$12K Hold
71
– – ﹤0.01% 112
2021
Q3 		$19K Buy
+71
New +$21.7K 0.01% 92

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pasadena Private Wealth's TCRT Position: Q2 2023 in Review

Pasadena Private Wealth sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 71 shares — an estimated $6.67K sold.

Pasadena Private Wealth first reported a position in TCRT in Q3 2021 and held it in 7 quarters. The position peaked at $19K in Q3 2021. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Pasadena Private Wealth reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Pasadena Private Wealth sold 71 Alaunos Therapeutics shares in Q2 2023, an estimated $6.67K.
  • Pasadena Private Wealth first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 7 quarters.
  • Pasadena Private Wealth's Alaunos Therapeutics position peaked at $19K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Pasadena Private Wealth's 13F filing for Q2 2023, filed 12 Jul 2023.